Trade Humacyte, Inc. - HUMA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.73 |
| Open | 3.74 |
| 1-Year Change | -22.41% |
| Day's Range | 3.52 - 3.76 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 3.52 | -0.25 | -6.63% | 3.77 | 3.79 | 3.52 |
| Feb 20, 2025 | 3.73 | -0.11 | -2.86% | 3.84 | 3.84 | 3.72 |
| Feb 19, 2025 | 3.85 | 0.15 | 4.05% | 3.70 | 3.86 | 3.70 |
| Feb 18, 2025 | 3.73 | -0.15 | -3.87% | 3.88 | 4.01 | 3.68 |
| Feb 14, 2025 | 3.89 | -0.04 | -1.02% | 3.93 | 4.12 | 3.86 |
| Feb 13, 2025 | 3.89 | -0.06 | -1.52% | 3.95 | 4.01 | 3.88 |
| Feb 12, 2025 | 3.95 | 0.02 | 0.51% | 3.93 | 4.09 | 3.86 |
| Feb 11, 2025 | 3.99 | -0.05 | -1.24% | 4.04 | 4.06 | 3.92 |
| Feb 10, 2025 | 4.10 | -0.04 | -0.97% | 4.14 | 4.25 | 4.01 |
| Feb 7, 2025 | 4.12 | -0.16 | -3.74% | 4.28 | 4.36 | 4.12 |
| Feb 6, 2025 | 4.25 | -0.06 | -1.39% | 4.31 | 4.42 | 4.20 |
| Feb 5, 2025 | 4.28 | -0.08 | -1.83% | 4.36 | 4.47 | 4.25 |
| Feb 4, 2025 | 4.34 | 0.05 | 1.17% | 4.29 | 4.41 | 4.27 |
| Feb 3, 2025 | 4.27 | -0.10 | -2.29% | 4.37 | 4.41 | 4.18 |
| Jan 31, 2025 | 4.56 | -0.16 | -3.39% | 4.72 | 4.82 | 4.48 |
| Jan 30, 2025 | 4.69 | 0.10 | 2.18% | 4.59 | 4.82 | 4.56 |
| Jan 29, 2025 | 4.54 | -0.06 | -1.30% | 4.60 | 4.70 | 4.50 |
| Jan 28, 2025 | 4.60 | 0.08 | 1.77% | 4.52 | 4.65 | 4.43 |
| Jan 27, 2025 | 4.49 | -0.01 | -0.22% | 4.50 | 4.75 | 4.42 |
| Jan 24, 2025 | 4.59 | 0.04 | 0.88% | 4.55 | 4.72 | 4.47 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Humacyte, Inc. Company profile
About Humacyte Inc
Humacyte, Inc. (Humacyte), formerly Alpha Healthcare Acquisition Corp., is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. The Company uses its technology platform to engineer and manufacture human acellular vessels (HAVs). The HAVs are designed to be implanted into any patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio (or cabinet) of HAVs with varying diameters and lengths. The HAV cabinet offers treatment solution in various clinical areas within vascular repair, reconstruction and replacement market, including trauma, AV access for hemodialysis, peripheral arterial disease (PAD), and coronary artery bypass grafting (CABG). In addition, the Company develops HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Humacyte Inc revenues increased from $0K to $1.1M. Net loss applicable to common stockholders increased from $19K to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items totaled to -$1.91.
| Industry: | Biotechnology & Medical Research (NEC) |
2525 East North Carolina Highway 54
DURHAM
NORTH CAROLINA 27713
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com